Could a malaria drug boost lung cancer treatment?
NCT ID NCT04648033
First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This early-phase trial tested the safety of adding atovaquone, a drug used for malaria, to standard chemoradiotherapy for people with locally advanced non-small cell lung cancer. The goal was to find the safest dose and see if it helps control the disease. Twenty-one participants were enrolled across three centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Churchill Hospital, Oxford University Hospitals
Oxford, OX3 7LE, United Kingdom
-
Guy's and St Thomas'
London, SE1 9RT, United Kingdom
-
Western General Hospital, NHS Lothian
Edinburgh, EH4 2XU, United Kingdom
Conditions
Explore the condition pages connected to this study.